EPIVIR-HBV
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIVIR-HBV is an oral small-molecule nucleoside reverse transcriptase inhibitor approved in 1998 for hepatitis B virus (HBV) infection. The drug works by inhibiting viral reverse transcriptase, reducing HBV replication and viral load in chronic HBV patients. It is a foundational antiviral therapy in the HBV treatment armamentarium.
LOE Approaching
As LOE approaches, the brand team is likely managing a mature, stable revenue base with shifting focus toward lifecycle management and defending market share against newer entrants.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career opportunities on EPIVIR-HBV are limited and focused on transition management rather than growth initiatives. Professionals assigned to this brand should expect a focus on cost optimization, generic transition planning, and defending existing market position in an increasingly competitive HBV space.
Brand Manager
Worked on EPIVIR-HBV at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.